A novel steroid medication that is used to treat Duchenne muscular dystrophy has showed great potential in treating inflammatory conditions including rheumatoid arthritis, according to preliminary study.
According to research published today in Rheumatology, the glucocorticoid vamorolone was found to be equally effective at treating inflammation as regular glucocorticoids, with fewer adverse effects. (Check the resource page below)
Among the most popular medications for treating a wide variety of inflammatory conditions are glucocorticoids. Regretfully, they can have serious adverse effects even though they efficiently relieve pain and inflammation. These include bone and muscle loss, which can raise the risk of fractures and falls.
The FDA has approved vamorolone, a special metabolism-resistant steroid that seems to have major anti-inflammatory effects with fewer negative effects on bone and muscle. (Read More)
Using animal models of persistent rheumatoid arthritis, the Foundation to Eradicate Duchenne-funded study demonstrates that vamorolone may be a viable substitute treatment for those who suffer from the condition.
